Purpose: To report our findings in a case of childhood refractory interstitial keratitis successfully treated with 0.1% topical tacrolimus.
Introduction
Interstitial keratitis, also known as immune stromal keratitis, is an inflammation of the corneal stroma without primary involvement of the corneal epithelium or endothelium. The pathogenic mechanism of interstitial keratitis is thought to be an antigen-antibodycomplement-mediated immune disease characterized by nummular opacities, stromal infiltrations, and immune rings. The chronicity of these reactions can lead to hypersensitive immune disease characterized by disciform edema and neovascularization of the stroma.
Before the introduction of antibiotics, syphilis was recognized as the most common cause of interstitial keratitis; however, recent reports indicate that herpes simplex virus (HSV) is now the leading cause of interstitial keratitis and is followed by idiopathic interstitial keratitis, syphilis, and varicella-zoster virus (VZV) 1 . The principle management of interstitial keratitis is with specific drugs against the causative agent combined with immune suppressants, such as corticosteroids and cyclosporine 2 4 .
We report a case of childhood interstitial keratitis that was successfully treated with topical 0.1% tacrolimus.
The interstitial keratitis was initially suspected to be zoster sine herpete that was refractory to corticosteroids and cyclosporine.
Case Report
The patient was a 12-year-old boy with recurrent interstitial keratitis who had been treated for 3 years with topical and systemic acyclovir, corticosteroids, and topical cyclosporine. He was referred to the Ehime University Hospital on September 14, 2007, at 9 years of age for uveitis of unknown cause and had been treated with topical 0.5% levofloxacin 3 times a day.
The protocol for the treatment of this case was approved by the institutional review board of Ehime University No. 1312004, and informed consent for the exami- intensive therapy, neovascularization and interstitial keratitis continued to recur (Fig. 4) .
Therefore, on December 28, 2010, the 0.5% topical cyclosporine (5 times a day) was replaced with topical 0.1% tacrolimus (2 times a day). Two weeks after the start of treatment with topical 0.1% tacrolimus, the neovascularization and interstitial keratitis improved and systemic steroid was tapered and stopped. Three months later, the interstitial keratitis had almost completely resolved and topical acyclovir and betamethasone began to be tapered (Fig. 5) . Since then, the patient has been treated with topical 0.1% tacrolimus (2 times a day) and topical 0.1% betamethasone (2 times a day) and tapered and stopped in 18 months. Since then, he has not shown any recurrence for 9 months, the best-corrected visual acuity improved to 24/20 OD and 24/20 OS, and the intraocular pressure was 10 mm Hg OD and 11 mm Hg OS on January 22, 2013 (Fig. 6) .
Discussion
Interstitial keratitis is a chronic corneal inflammation that can lead to severe corneal scarring and visual decrease.
At present, the most common cause of interstitial keratitis is HSV, and HSV-interstitial keratitis is treated with antiviral drugs and immune suppressants, such as corti- In the present case, a definitive diagnosis could not be made because there was no unambiguous serological data, but interstitial keratitis caused by zoster sine herpete may be suspected by the typical clinical course. The effectiveness of cyclosporine A against refractory interstitial keratitis due to HSV has been demonstrated 4 ; however, topical cyclosporine had no effect in the present case.
Tacrolimus is a potent immunosuppressive macrolide, and its mechanism of action is similar to that of cyclosporine. However, the potency of tacrolimus is 30 times greater than that of cyclosporine 6 . Its clinical efficacy has been demonstrated against refractory ocular surface inflammatory diseases 7 9 . Therefore, we replaced topical cyclosporine with topical tacrolimus, which was extremely effective against the uncontrolled deep stromal keratitis. The effectiveness of tacrolimus supports our hypothesis that our case was a herpes infection because tacrolimus is known to inhibit the transcription of interleukin 2, which inhibits the proliferation of T lymphocytes 10 . Although the exact mechanism of how VZV causes interstitial keratitis is not known, it has been suggested that interleukin 2-mediated T lymphocytes play an important role in interstitial keratitis due to HSV 2, 11, 12 .
In conclusion, our case of childhood refractory interstitial keratitis was most likely due to zoster sine herpete and was successfully treated with 0.1% topical tacrolimus. Thus, topical tacrolimus should be considered in treating cases of childhood refractory interstitial keratitis.
